Reported 30 days ago
Pfizer's upcoming quarterly financial report is crucial as activist hedge fund Starboard Value intensifies demands for evidence of a turnaround under CEO Albert Bourla. Investors expect improved profitability and revenue growth, especially from recent cancer drug acquisitions, following significant cost cuts. The company's stock remains significantly lower than its pandemic highs, affected by declining COVID-19 sales. Analysts suggest that successful integration of newly acquired assets and a clearer focus on key therapeutic areas are essential for regaining investor confidence and ensuring continued dividend performance.
Source: YAHOO